Simultaneous use of erythropoietin and LFM-A13 as a new therapeutic approach for colorectal cancer

What is it about?

Despite the use of combination therapy in many patients with colon cancer, satisfactory results are not fully achieved.For the first time, we provide unprecedented evidence that simultaneous use of Epo and LFM-A13 significantly intensify anticancer activity of LFM-A13. It is worth noting the beneficial effect of adding Epo, which not only enhanced the antitumor effect of LFM-A13 but also showed high-profile safety with no induced nephrotoxicity, hepatotoxicity, or changes in the hematological profile. We come to the conclusion that Epo, as an adjunct to LFM-A13, has synergistic effects on colon cancer, indicating that this therapeutic scheme may improve treatment outcome as well as the quality of life in cancer patients.

Featured Image